Drug Trial Radar · NCT07587515
Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
May 19, 2026
Primary completion
May 2028
Study completion May 2028
Sponsor
- Lead sponsor
- Eyconis INC.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
Conditions
- Neovascular (Wet) Age-Related Macular Degeneration
Interventions
EYC-0305Biological
Extended-delivery anti-VEGF
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of ocular treatment-emergent adverse events (TEAEs)Time frame: Week 72
- Incidence and severity of systemic treatment-emergent adverse events (TEAEs)Time frame: Week 72
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Beverly Hills, CA
Beverly Hills, California · Recruiting
Modesto, CA
Modesto, California · Recruiting
Wake Forest, NC
Wake Forest, North Carolina · Recruiting
Erie, PA
Erie, Pennsylvania · Recruiting
Bellaire, TX
Bellaire, Texas · Recruiting
McAllen, TX
McAllen, Texas · Recruiting
The Woodlands, TX
The Woodlands, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.